TriSalus Life Sciences Inc expected to post a loss of 15 cents a share - Earnings Preview

TriSalus Life Sciences

04/08/2026 22:08

TriSalus Life Sciences Inc TLSI.OQ TLSI.O is expected to  show a fall in quarterly revenue when it reports  results on August 6 for the period ending June 30 2026
The Westminster Colorado-based  company is expected to report a 8.4% decrease in revenue to $10.267 million from $11.21 million a year ago, according to the mean estimate from 4 analysts, based on LSEG data.
​LSEG's mean analyst estimate for TriSalus Life Sciences Inc is for a loss of 15 cents per share. 
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."  
The mean earnings estimate of analysts was unchanged in the last three months. ​
Wall Street's median 12-month price target for TriSalus Life Sciences Inc is $9.00, about 89.5% above its last closing price of $4.75
Previous quarterly performance (using preferred earnings measure in US dollars). ​
QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE 
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2026
-0.15
-0.16
0.03
Beat
119.2
Dec. 31 2026
-0.14
-0.13
-0.21
Missed
-59.5
Sep. 30 2025
-0.16
-0.15
-0.25
Missed
-68.3​
Jun. 30 2025
-0.23
-0.22
-0.27
Missed
-23.5
​​Mar. 31 2025
-0.22
-0.22
-0.39
Missed
-77.3
Dec. 31 2024
-0.34
-0.32
-0.40
Missed
-26​
Sep. 30 2024
-0.35
-0.35
-0.12
Beat
65.3
Jun. 30 2024
-0.49
-0.49
-0.21
Beat
57.4
This summary was machine generated August 4 at 21:08 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)